Tetrahydropyranyladriamycin (THP-adriamycin) is an anthracycline analogue currently under development in Europe and Japan. Preclinical studies suggest that it may have greater activity and less cardiac toxicity than doxorubicin. We conducted a phase I clinical and pharmacologic study of THP-adriamycin given as a weekly 15-min infusion for 3 weeks, followed by 1 week of observation. Therapy was associated with minimal acute toxicity. The dose-limiting toxicity was neutropenia, usually maximal during the 4th week after treatment; alopecia was rare. The maximum tolerated dose was 25 mg/m2; for phase II studies using this schedule, a dose of 20 mg/m2 weekly for 3 weeks is recommended. Pharmacokinetic studies revealed a triphasic elimination of the parent compound with α, β, and γ half-lives of 5.6 min, 1.4 h, and 9.3 h, respectively. THP-adriamycin was rapidly taken up by blood cell components, with concentrations in red blood cells (RBCs), lymphocytes, and polymorphonuclear cells exceeding those in plasma. In all, <10% of the compound was eliminated in the urine within 24 h.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
high-pressure liquid chromatography
area under the curve
volume of distribution
polymorphonuclear neutrophil lymphocytes
red blood cell
Boyum A (1968) Separation of leukocytes from blood and bone marrow. Scand J Clin Lab Invest 21 [Suppl 97]: 77–83
Bristow MR, Mason JW, Billingham ME, Danials JR (1978) Adriamycin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy and cardiac catheterization. Ann Intern Med 88: 168–175
Dantchev D, Paintrand M, Hayat M, Bourut C, Mathé G (1979) Low heart and skin toxicity of a tetrahydropyranyl derivative of adriamycin (THP-ADM) as observed by electron and light microscopy. J Antibiot (Tokyo) 32: 1085
Fujita H, Ogawa K, Tone H, Iguchi H, Shomura T, Murata S (1986) Pharmacokinetics of doxorubicin, (2″R)-4′-0-tetrahydropyranyladriamycin and adarubicin. Jpn J Antibiot 39: 1321–1336
Hisamatsu T, Suzuki K, Sakakibara S, Komuro K, Nagasawa M, Takeuchi T, Umezawa H (1985) Antitumor spectrum of a new anthracycline, (2″R)-4′-0-tetrahydropyranyladriamycin, and effect on the cellular immune response in mice. Jpn J Cancer Res 76: 1008–1020
Iguchi H, Tone H, Ishikura T, Takeuchi T, Umezawa H (1985) Pharmacokinetics and disposition of 4′-0-tetrahydropyranyladriamycin in mice by HPLC analysis. Cancer Chemother Pharmacol 15: 132–140
Iguchi H, Tone H, Kiyosaki T, Ishikura RT, Takeuchi T, Umezawa H (1986) Pharmacokinetics and disposition of (2″R)-4′-0-tetrahydropyranyladriamycin in dogs. Jpn J Antibiot 39: 638–652
Kunimoto S, Miura K, Takahashi Y, Takeuchi T, Umezawa H (1983) Rapid uptake by cultured tumor cells and intracellular behavior of 4′0-tetrahydropyranyladriamycin. J Antibiot (Tokyo) 36: 312–317
Majima H (1984) Clinical and clinical pharmacologic studies of 4′-0-tetrahydropyranyl doxorubicin (THP-ADM). Proc Am Soc Clin Oncol 3: 20
Matsushita Y, Iguchi H, Kiyosaki T, Tone H, Ishikura T (1983) A high performance liquid chromatographic method of analysis of 4′-0-tetrahydropyranyladriamycin and metabolites in biological samples. J Antibiot (Tokyo) 36: 880–886
Miller AA, Schmidt CG (1987) Clinical pharmacology and toxicity of 4′-0-tetrahydropyranyladriamycin. Cancer Res 47: 1461–1465
Ogawa M, Miyamoto H, Inigaki J, Horikoshi N, Ezaki K, Inoue K, Ikeda K, Usui N, Nakada H (1983) Phase I clinical trial of a new anthracycline: 4′-0-tetrahydropyranyl adriamycin. Invest New Drugs 1: 169–172
Tapiero H, Munck JN, Bennoun M, Mathé G (1984) Differences in cellular uptake of adriamycin, THP-adriamycin and 4-epi-adriamycin in sensitive and ADM-resistant Friend leukemia cells: relationship with the cytotoxic activity. Proc Am Assoc Cancer Res 25: 307
Umezawa H, Takashi Y, Kinoshita M, Naganawa H, Masuda T, Ishizuka M, Takastu K, Takeuchi T (1979) Tetrahydropyranyl derivatives of daunomycin and adriamycin. J Antibiot (Tokyo) 32: 1082–1084
Umezawa H, Yamada K, Oki T (1983) Comparative experimental studies on 4′-0-tetrahydropyranyl-adriamycin and adriamycin. In: Mathé G, Maral R, De Jager R (eds) Anthracyclines. Current Masson Publishing USA Inc., New York, pp 183–188
WHO Handbook for Standardized Cancer Registries (hospital-based) (1976) World Health Organization, Geneva (Offset Publication 25)
Supported in part by a National Cancer Institute Research Career Development Award (KO4 CA 01135) to R. A. Newman
About this article
Cite this article
Raber, M.N., Newman, R.A., Lu, K. et al. Phase I clinical trial and pharmacokinetic evaluation of 4′-0-tetrahydropyranyladriamycin (THP-adriamycin). Cancer Chemother. Pharmacol. 23, 311–315 (1989). https://doi.org/10.1007/BF00292410
- Acute Toxicity
- Parent Compound